Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 433-441

  Hiramine, Yasunari ^a,b   Uto, Hirofumi ^b   Imamura, Yasushi ^a   Tabu, Kazuaki ^a,b   Baba, Yoshirou ^a   Hiwaki, Takuya ^a   Sho, Yukihiko ^a   Tahara, Kenji ^a   Higashi, Hirofumi ^c   Tamai, Tutomu ^b   Oketani, Makoto ^b   Ido, Akio ^b   Tsubouchi, Hirohito ^b  

^a Kagoshima Kouseiren Hospital   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF FITNESS AND SPORTS IN KANOYA   (Japan)

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Prognosis; Side effect; Sorafenib

Indexed keywords

CISPLATIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN C; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG WITHDRAWAL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; SINGLE DRUG DOSE; SKIN DISEASE; SOLID TUMOR; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79953274309     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.237     Document Type: Article

References (37)

1. Cabibbo G, Latteri F, Antonucci M and Craxì A: Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol 6: 159-169, 2009.
2. Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH and Han KH: Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol: June 16, 2010 (Epub ahead of print).
3. Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M and Sasaki Y: Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 45: 60-67, 2010.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: SHARP investigators study group: sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
6. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J and Gores GJ: Panel of experts in HCC-design clinical trials: design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
7. Kudo M: The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular-targeted therapy. J Gastroenterol Hepatol 25: 439-452, 2010.
8. Cabrera R and Nelson DR: The management of hepatocellular carcinoma. Aliment Pharmacol Ther 31: 461-476, 2010.
9. Urabe T, Kaneko S, Matsushita E, Unoura M and Kobayashi K: Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55: 39-47, 1998.
10. Kuroda M, Kobayashi Y, Urawa N, Yamamoto M, Mifuji R, Araki J, Tanaka H, Horiike S, Itani T, Furjita N, Konishi M, Iwasa M, Kaito M and Adachi Y: Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. Hepatogastroenterology 54: 518-521, 2007.
11. Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, Toyota N, Ito K and Chayama K: Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42: 845-853, 2007.
12. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95: 588-595, 2002.
13. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, Ochi K, Kiura K and Tanimoto M: Combination chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular carcinoma. Anticancer Res 23: 1891-1897, 2003.
14. Yoshikawa M, Ono N, Yodono H, Ichida T and Nakamura H: Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38: 474-483, 2008.
15. Kondo M, Nagano H, Sakon M, Yamamoto H, Morimoto O, Arai I, Miyamoto A, Eguchi H, Dono K, Nakamori S, Umeshita K, Wakasa K, Ohmoto Y and Monden M: Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Int J Oncol 17: 83-88, 2000.
16. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K and Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93: 557-564, 2005.
17. Kudo M: Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice. Int J Clin Oncol 15: 242-255, 2010.
18. Shen YC, Hsu C and Cheng AL: Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 45: 794-807, 2010.
19. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM and Han KH: Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110: 129-137, 2007.
20. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99: 159-165, 2008.
21. Ando E, Yamashita F, Tanaka M and Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 79: 1890-1896, 1997.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Rreatment of Cancer, national Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
23. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 9 (Suppl. 3): S1-S82, 2004 (In Japanese).
24. Rouillier P, Senesse P, Cottet V, Valléau A, Faivre J and Boutron-Ruault MC: Dietary patterns and the adenomacarcinoma sequence of colorectal cancer. Eur J Nutr 44: 311-318, 2005.
25. Furuse J: Sorafenib for the treatment of unresectable hepatocellular-carcinoma. Biologics 2: 779-788, 2008.
26. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, de Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006.
27. Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ and Chang JW: Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158: 592-596, 2008.
28. Hakamada K, Kimura N, Miura T, Morohashi H, Ishido K, Nara M, Toyoki Y, Narumi S and Sasaki M: Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 14: 1370-1377, 2008.
29. Bruix J and Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524, 2002.
30. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, Im HU, Choi JY, Yoon SK, Cheong JY, Cho SW, Jang BK, Hwang JS, Kim SG, Kim YS, Seo YS, Yim HJ and Um SH: A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 65: 373-382, 2010.
31. Kudo M and Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 78 (Suppl. 1): S154-S166, 2010.
32. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B and Saltz LB: Doxorubicin plus sorafenib vs. doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160, 2010.
33. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, del Prete S and Tonini G: Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologis 15: 85-92, 2010.
34. La Vine DB, Coleman TA, Davis CH, Carbonell CE and Davis WB: Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 33: 217-220, 2010.
35. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K and Mizokami M: Lambda-interferons and the single nucleotide polymorphisms: a milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 40: 449-460, 2010.
36. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N and Kumada H: Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 44: 952-963, 2009.
37. Villanueva A, Minguez B, Forner A, Reig M and Llovet JM: Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61: 317-328, 2010.